Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/121021
Title: | Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial |
Author: | Leyes, Pere Martínez Chamorro, Esteban José Larrousse Morellón, Maria Cofán Pujol, Montserrat Trabal, Joan Pérez-Heras, Ana Maria Forga, María T. Ros Rahola, Emilio |
Keywords: | Colesterol Persones seropositives Trastorns del metabolisme dels lípids Cholesterol HIV-positive persons Lipid metabolism disorders |
Issue Date: | 11-Sep-2014 |
Publisher: | BioMed Central |
Abstract: | BACKGROUND: The effects of ezetimibe on cholesterol metabolism in HIV-infected patients receiving boosted protease inhibitors have not been thoroughly assessed. The aim of this study was to assess cholesterol homeostasis in patients with PI associated dyslipidemia and its relationship with the response to treatment with the cholesterol-absorption inhibitor ezetimibe. METHODS: Fifteen patients with ritonavir-boosted PI-containig therapy and LDL-cholesterol > 3.36 mmol/L (>130 mg/dL) were assessed at baseline and after an 8-week course of ezetimibe 10 mg/d. Serum non-cholesterol sterols were measured at each visit as markers of cholesterol synthesis and absorption. Total-, LDL-, and HDL-cholesterol triglycerides, apolipoproteins A1 and B, high sensitivity C-reactive protein, CD4 cells and HIV-1 RNA were also measured. RESULTS: Ezetimibe treatment was well tolerated in all patients and resulted in significant reductions in total cholesterol (-11.4%, p = .002), LDL-cholesterol (-20.4%, p = .003), non-HDL-cholesterol (-13.4%, p = .002) and apolipoprotein B (-9.1%, p = .021). Treatment with ezetimibe was associated with decreased cholesterol absorption markers (campesterol-to-cholesterol ratio -43.0%, p = .001; sitosterol-to-cholesterol ratio -41.9%, p = .001) and increased synthesis markers (lathosterol-to-cholesterol ratio 53.2%, p = .005). Baseline absorption or synthesis markers were unrelated to the response to treatment. CD4 cell count and plasma HIV-1 RNA remained unchanged. CONCLUSIONS: The level of cholesterol absorption or synthesis does not appear to be a major determinant of the responsiveness to ezetimibe in patients on ritonavir-boosted PI-containing therapy. |
Note: | Reproducció del document publicat a: https://doi.org/10.1186/1471-2334-14-497 |
It is part of: | Bmc Infectious Diseases, 2014, vol. 14, p. 497 |
URI: | http://hdl.handle.net/2445/121021 |
Related resource: | https://doi.org/10.1186/1471-2334-14-497 |
ISSN: | 1471-2334 |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
647626.pdf | 292.64 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License